BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38563164)

  • 1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
    Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
    Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
    Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
    Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
    ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers.
    Fondevila F; Méndez-Blanco C; Fernández-Palanca P; González-Gallego J; Mauriz JL
    Exp Mol Med; 2019 Sep; 51(9):1-15. PubMed ID: 31551425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib in glioblastoma recurrence: A case report.
    Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
    Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
    Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G
    Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of regorafenib and its current and potential future role in cancer therapy.
    Davis SL; Eckhardt SG; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
    Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
    De Felice M; De Marinis P; Martin G; Bruscella S; De Bellis A; Poliero L; Turitto G
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5008-5013. PubMed ID: 35916797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.